Avidity Biosciences
About: Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Employees: 253
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
176% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 25
43% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $7.5M
33% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 63
24% more capital invested
Capital invested by funds: $4.64B [Q2] → $5.75B (+$1.11B) [Q3]
22% more funds holding
Funds holding: 196 [Q2] → 240 (+44) [Q3]
11% more funds holding in top 10
Funds holding in top 10: 9 [Q2] → 10 (+1) [Q3]
11.87% less ownership
Funds ownership: 118.83% [Q2] → 106.95% (-11.87%) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$60
91%
upside
Avg. target
$68
118%
upside
High target
$78
149%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 102 / 328 met price target | 130%upside $72 | Buy Initiated | 20 Dec 2024 |
RBC Capital Luca Issi 23% 1-year accuracy 13 / 56 met price target | 114%upside $67 | Outperform Initiated | 26 Nov 2024 |
Chardan Capital Keay Nakae 31% 1-year accuracy 22 / 72 met price target | 107%upside $65 | Buy Maintained | 13 Nov 2024 |
Needham Joseph Stringer 26% 1-year accuracy 33 / 127 met price target | 91%upside $60 | Buy Reiterated | 13 Nov 2024 |
TD Cowen Ritu Baral 38% 1-year accuracy 3 / 8 met price target | 149%upside $78 | Buy Maintained | 21 Oct 2024 |
Financial journalist opinion
Based on 3 articles about RNA published over the past 30 days
Neutral
PRNewsWire
4 days ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Dec. 20, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on December 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 720,400 shares of its common stock and 276,200 restricted stock units ("RSUs") to thirty-seven (37) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Seeking Alpha
2 weeks ago
Avidity Biosciences Advances With FDA Clearance And Promising Data For Rare Diseases
Avidity Biosciences' AOC platform targets genetic diseases by combining monoclonal antibodies with oligonucleotide therapies, overcoming traditional delivery limitations. Del-brax (AOC 1020) for FSHD showed a 50% reduction in DUX4 gene expression, positioning it as a potential best-in-class therapy. Del-desiran (AOC 1001) for DM1 cleared the FDA's clinical hold, enabling progression to Phase 3 HARBOR trials with favorable regulatory designations.
Neutral
PRNewsWire
4 weeks ago
Avidity Biosciences to Participate in Upcoming Investor Conference
SAN DIEGO , Nov. 26, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference: 7th Annual Evercore ISI HealthCONx Conference on December 3 at 9:30 a.m. PT / 12:30 p.m.
Neutral
PRNewsWire
1 month ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Nov. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on November 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 117,000 shares of its common stock and 58,500 restricted stock units ("RSUs") to twelve (12) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Zacks Investment Research
1 month ago
RNA Stock Hits Record High on Entering the Cardiac Disease Space
Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies.
Positive
Investors Business Daily
1 month ago
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space. The post Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News appeared first on Investor's Business Daily.
Neutral
PRNewsWire
1 month ago
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN Cardiomyopathy and AOC 1072 to treat PRKAG2 Syndrome AOC 1072 and AOC 1086 preclinical data demonstrated robust siRNA delivery to the heart and targeted knockdown with potent reduction of approximately 80% in cardiac PLN mRNA and PRKAG2 mRNA Avidity introduces next-generation technology innovations demonstrating improved siRNA delivery in skeletal muscle and increased durability in preclinical studies AOC 1072 preclinical data will be presented at American Heart Association (AHA) Scientific Sessions 2024 Volume 11 of virtual investor and analyst series today, Tuesday, Nov. 12 at 8:00 a.m. ET SAN DIEGO , Nov. 12, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it has expanded beyond rare skeletal muscle disorders and is opening up a new therapeutic field, precision cardiology, to address the root cause of genetic diseases of the heart.
Negative
Zacks Investment Research
1 month ago
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.71 per share a year ago.
Neutral
PRNewsWire
1 month ago
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
Enrollment in global Phase 3 HARBOR™ study for del-desiran in DM1 is on track Avidity initiated biomarker cohort for del-brax FORTITUDE™ study for FSHD; pursuing a potential accelerated approval path for del-brax Reported positive del-zota data from Phase 1/2 EXPLORE44™ trial for DMD44 Avidity to provide a first look at precision cardiology candidates and a glimpse at next-generation technology innovations via webcast event November 12, 2024 SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the third quarter ended September 30, 2024, and highlighted recent corporate progress. "We are executing three potentially registrational clinical trials in three rare diseases where there are limited or no therapeutic options available.
Negative
Zacks Investment Research
1 month ago
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charts implemented using Lightweight Charts™